- $19.98m
- $10.71m
- $57.57m
Brief: Aytu Biopharma Delivers Written Notice To Jefferies To Terminate Sales Agreement Dated June 5, 2020 Effective June 2, 2021
Aytu Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 31 cents a share - Earnings Preview
Aytu Biopharma Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Aytu Bioscience Says David Green Resigned As Chief Financial Officer
Brief: Acerus Buys Back All Remaining U.S. Rights For Natesto From Aytu
Brief: Aytu Bioscience Inc - Q2 Net Revenue $15.1 Million, Compared To $13.5 Million In Q1 2021
Brief: Aytu Bioscience And Neos Therapeutics Announce Special Meetings Of Stockholders Related To Proposed Merger To Be Held On March 18, 2021
Brief: Aytu Bioscience Inc - On January 20, 2021, Co Signed An Exclusive License Agreement
Brief: Armistice Capital Llc Reports A Stake Of 7.7% In Aytu Bioscience As Of Dec. 11 - SEC Filing
U.S. STOCKS ON THE MOVE-Nabriva Therapeutics, GigCapital3, Fat Brands, Niocan
U.S. STOCKS ON THE MOVE-Facebook, Disney, CureVac, Chevron
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM
Aytu BioScience: Rises on merger deal with Neos Therapeutics
U.S. STOCKS ON THE MOVE-Boeing, Disney, Pfizer, Eli Lilly
Aytu BioScience Inc: Up on deal for EUA authorized COVID-19 antigen tests